Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer

Clinical trial NCT06026657 · RECRUITING

Trial details

NCT number: NCT06026657
Sponsor: Margaret Gatti-Mays
Status: RECRUITING
Phase: Phase 1, Phase 2
Study type: INTERVENTIONAL

Anatomic Stage IV Breast Cancer AJCC v8 HER2-Negative Breast Carcinoma

Start date: 2024-04-02
Primary completion: 2027-10-31
Enrollment: 42

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.